

Reference Sheet

Information

Chronic Hepatitis C (HCV) treatment prescribing is getting even easier for GP's. The new pan-genotypic direct acting agent (DAA) regime sofosbuvir/velpatasvir (trade name Epclusa) is a one tablet a day, 12 weeks regime, with over 95% cure rates for **all genotypes (1-6)** with minimal side effects.

If you are not confident treating you can [Obtain Specialist Approval for Initiation of Hepatitis C Treatment in 24 hours via online REACH-C form in Australia](#)

It is so satisfying as a GP to be able to cure a chronic disease and be involved in the private journey in the one stop shop primary care model. The **APRI score app** (AST/Platelet ratio) can be used as a surrogate indicator of the likelihood of cirrhosis and determine who needs a fibroscan pre-treatment. **The majority no longer need a fibroscan pre-treatment.**

Together we can meet the 2030 target to eliminate chronic Hep C in Australia. 20% of people living with chronic HCV are not yet diagnosed and 170,000 still need to be treated.

Please refer to the simple step workup and treatment pathway on the PHN portal with references to GP resources and education sessions.

Contact for further information

Name: Dr Annie Balcomb, GPLO WNSWPHN/WNSLHD

Other email annie.balcomb@wnswphn.org.au